Halozyme Names Ex-Incyte Commercial Chief Jim Daly to Board
San Diego – September 30, 2026 -- Halozyme Therapeutics (Nasdaq: HALO) has appointed James "Jim" Daly to its Board of Directors, returning a veteran biopharmaceutical commercial executive to help steer the company's drug-delivery technology expansion.
Daly rejoins board after prior tenure, bringing three decades of launch experience
Daly previously served on Halozyme's board and has held senior commercial leadership roles at Incyte Corporation, Amgen and Glaxo Wellcome/GlaxoSmithKline. He was Executive Vice President and Chief Commercial Officer of Incyte from 2012 to 2015, following a decade at Amgen where he most recently served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier, he spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, including as Senior Vice President and General Manager of the U.S. respiratory business.